Drug Trial Radar · NCT07912593
A KRAS Inhibitor in Participants With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
320
Planned (sponsor's estimate)
Start
Oct 22, 2026
Primary completion
Oct 30, 2028
Study completion Apr 30, 2029
Sponsor
- Lead sponsor
- Ensem TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Nov 3, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/2, open-label, multi-center study to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of ETX-929 in participants with advanced solid tumors harboring a Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation.
Conditions
- Metastatic Colorectal Cancer (CRC)
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Non-squamous, Non-Small Cell Lung Cancer
- Endometrial Adenocarcinoma
- Ovarian Adenocarcinoma
- Primary Peritoneal Carcinoma
Interventions
ETX-929 dose escalationDrug
ETX-929 is a pan-KRAS Inhibitor in the form of an oral capsule that will be taken once per day in 21-day cycles, to evaluate escalating dose levels.
ETX-929 dose escalation in combination with cetuximabDrug
ETX-929 is a pan-KRAS Inhibitor in the form of an oral capsule. ETX-929 will be taken in combination with cetuximab in 28-day cycles, to evaluate escalating dose levels. EXT-929 is an oral capsule that will be taken once per day. Cetuximab will be administered intravenously every two weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate Safety and Tolerability of ETX-929 monotherapy in Part A and ETX-929 plus cetuximab combination therapy in Part BTime frame: First Cycle (21 days in Part A and 28 days in Part B)
- Evaluate Safety and Tolerability of ETX-929 monotherapy in Part A and ETX-929 plus cetuximab combination therapy in Part BTime frame: Average of 6 months
- Select the Recommended Phase 2 Dose(s) (RP2D)Time frame: Average of 6 months
- Evaluate efficacy of ETX-929 monotherapy and ETX-929 in combination with cetuximab at the RP2D(s) in Part B and Part DTime frame: Average of 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
NEXT
Fairfax, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.